TRANSTHERA-B (02617.HK) HKEX approves H-share full circulation of 44.97m shares
NewTimeSpace News: On 1 November 2026, TransThera Sciences (Nanjing), Inc. (02617.HK) disclosed that the HKEX has granted approval for the listing and trading of 44,971,128 H shares converted from unlisted shares held by 10 shareholders.
The listing approval was granted on 30 October 2026, with the shares representing about 11.01% of the total issued share capital. Among them, CPE Investment (Hong Kong) 2021 Limited holds 21,521,091 shares (about 5.27%) and Shanghai Guoxin Investment Development Co., Ltd. holds 8,314,088 shares (about 2.03%), with the remaining participating shareholders each holding less than 1%.
After the conversion, the company's H shares will rise from 313,347,673 (about 76.69%) to 358,318,801 (about 87.70%), while unlisted shares will fall from 95,230,960 (about 23.31%) to 50,259,832 (about 12.30%). The company will complete the conversion procedures and publish further announcements in due course.
- TransThera-B (02617.HK): Yochanra® begins nationwide sales
- TRANSTHERA-B (02617.HK): Tinengotinib Included in CSCO Guidelines for Biliary Tract Malignancies (2026)
- TRANSTHERA-B(02617.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at loss of CNY 95.47 million, loss narrowed by 22.3% YoY
- TRANSTHERA-B (02617.HK): Class 1 New Drug Jientai (Tiengotinib Tablets) Receives Conditional NMPA Approval for FGFR2 Fusion Advanced Cholangiocarcinoma
- TRANSTHERA-B (02617.HK) plans to issue in total 3.84 million shares by placement, with estimated net proceeds of HKD 152.13 million
